These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10767361)

  • 21. Delayed emesis following anticancer chemotherapy.
    Kris MG; Roila F; De Mulder PH; Marty M
    Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is oral ondansetron really efficacious in the control of cisplatin-induced delayed emesis?
    Martin M
    J Clin Oncol; 1996 Apr; 14(4):1401-2. PubMed ID: 8648398
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
    Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
    Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia.
    Pivot X; Guardiola E; Etienne M; Thyss A; Foa C; Otto J; Schneider M; Magné N; Bensadoun RJ; Renée N; Milano G
    Eur J Cancer; 2000 May; 36(7):852-7. PubMed ID: 10785589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
    Kenward H; Elliott J; Lee T; Pelligand L
    BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
    Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
    Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research.
    Roila F
    Oncology; 1996 Jun; 53 Suppl 1():65-72. PubMed ID: 8692554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients.
    Alfieri AB; Cubeddu LX
    Br J Cancer; 1995 Oct; 72(4):1013-5. PubMed ID: 7547213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal control of acute cisplatin-induced emesis.
    Verweij J; de Wit R; de Mulder PH
    Oncology; 1996 Jun; 53 Suppl 1():56-64. PubMed ID: 8692553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.